Erfan Nur

Erfan Nur

Auto-generated profile, based on publicly available information

Erfan Nur

Department of Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2011 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
ENErfan Nur
Erfan Nur
BBBart J. Biemond
Bart J. Biemond
HOHans‐Martin Otten
Hans‐Martin Otten
DBDees P. Brandjes
Dees P. Brandjes
JSJohn‐John B. Schnog
John‐John B. Schnog
TGthe CURAMA Study Group
the CURAMA Study Group

1 September 2019 in Blood Reviews
Verified
Journal Article
Closed access
MHM.E. Houwing
M.E. Houwing
PPP.J. de Pagter
P.J. de Pagter
EBEduard J. van Beers
Eduard J. van Beers
BBB.J. Biemond
B.J. Biemond
ERE. Rettenbacher
E. Rettenbacher
MCM.H. Cnossen
M.H. Cnossen

8 April 2020 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
ENErfan Nur
Erfan Nur
AGAafke E. Gaartman
Aafke E. Gaartman
CTCharlotte F. J. van Tuijn
Charlotte F. J. van Tuijn
MTMan Wai Tang
Man Wai Tang
BBBart J. Biemond
Bart J. Biemond
Click on the book chapter title to read more.

20 June 2024 in Blood
Verified
Journal Article
Closed access
PDF file
AKAdetola A Kassim
Adetola A Kassim
JFJosu de la Fuente
Josu de la Fuente
ENErfan Nur
Erfan Nur
KWKarina L. Wilkerson
Karina L. Wilkerson
AAAli D. Alahmari
Ali D. Alahmari
MDMichael DeBaun
Michael DeBaun
In the setting of a learning collaborative, we conducted an international multicenter phase 2 clinical trial testing the hypothesis that nonmyeloablative–related haploidentical bone marrow transplant (BMT) with thiotepa and posttransplant cyclophosphamide (PTCy) will result in 2-year event-free survival (no graft failure or death) of at least 80%. A total of 70 participants were evaluable based on the conditioning protocol. Graft failure occurred in 8 of 70 (11.4%) and only in participants aged <18 years; all had autologous reconstitution. After a median follow-up of 2.4 years, the 2-year Kaplan-Meier–based probability of event-free survival was 82.6%. The 2-year overall survival was 94.1%, with no difference between children and adult participants. After excluding participants with graft failure (n = 8), participants with engraftment had median whole blood donor chimerism values at days +180 and +365 after transplant of 100% (n = 58), respectively, and 96.6% (57/59) were off immunosuppression 1 year after transplant. The 1-year grade 3 to 4 acute graft-versus-host disease (GVHD) rate was 10%, and the 2-year moderate–severe chronic GVHD rate was 10%. Five participants (7.1%) died from infectious complications. We demonstrate that nonmyeloablative haploidentical BMT with thiotepa and PTCy is a readily available curative therapy for most adults, even those with organ damage, compared to the more expensive myeloablative gene therapy and gene editing. Additional strategies are required for children to decrease graft failure rates. The trial was registered at www.clinicaltrials.gov as #NCT01850108.

1 November 2011 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
ENErfan Nur
Erfan Nur
MVMirjam Verwijs
Mirjam Verwijs
DWDirk R. de Waart
Dirk R. de Waart
JSJohn-John B. Schnog
John-John B. Schnog
HOHans-Martin Otten
Hans-Martin Otten
RERonald P.J. Oude Elferink
Ronald P.J. Oude Elferink

16 April 2022 in American Journal of Hematology
Verified
Journal Article
Closed access
MDMyrthe J. van Dijk
Myrthe J. van Dijk
MRMinke A.E. Rab
Minke A.E. Rab
BOBrigitte A. van Oirschot
Brigitte A. van Oirschot
JBJennifer Bos
Jennifer Bos
CDCleo Derichs
Cleo Derichs
EBEduard J. van Beers
Eduard J. van Beers